Señales en vivo de LPGO.ST | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 abr 2024 @ 11:15):

Stats
Volumen de hoy	614 831
Volumen promedio	538 035
Capitalización de mercado	45.45M
EPS	SEK0 ( 2024-02-22 )
Próxima fecha de ganancias	( SEK0 ) 2024-05-24
Last Dividend	SEK0 ( N/A )
Next Dividend	SEK0 ( N/A )
P/E	-1.890
ATR14	SEK0.00900 (2.50%)

Volumen Correlación

Largo: -0.06 (neutral)

Corto: -0.59 (weak negative)

Signal:(58.156) Neutral

Lipigon Pharmaceuticals Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lipigon Pharmaceuticals Correlación - Moneda/Commodity

0.14
( neutral )

0.08
( neutral )

0.00
( neutral )

-0.09
( neutral )

Lipigon Pharmaceuticals Finanzas

Annual	2023
Ingresos:	SEK16.41M
Beneficio Bruto:	SEK-12.58M (-76.66 %)
EPS:	SEK-0.190

FY	2023
Ingresos:	SEK16.41M
Beneficio Bruto:	SEK-12.58M (-76.66 %)
EPS:	SEK-0.190

FY	2022
Ingresos:	SEK390 000
Beneficio Bruto:	SEK366 000 (93.85 %)
EPS:	SEK-2.12

FY	2021
Ingresos:	SEK3.18M
Beneficio Bruto:	SEK0.00 (0.00 %)
EPS:	SEK-4.56

Financial Reports:

No articles found.

Lipigon Pharmaceuticals

Lipigon Pharmaceuticals AB (publ) develops drugs for lipid related diseases in Sweden. The company's product pipeline consists of Lipisense project for the treatment of severe hypertriglyceridemia disease and familial chylomicronemia syndrome; a gene therapy project for the lipodystrophy, a rare disease of altered fat distribution in the body; therapeutics for dyslipidemia, a general lipid disorder; and RNA drug project for acute respiratory distress syndrome. Lipigon Pharmaceuticals AB (publ) has a collaboration agreement with HitGen Inc. for the development of small molecules for the treatment of dyslipidemia, cardiovascular disease, and other metabolic diseases. The company was founded in 2010 and is based in Umeå, Sweden.